Haw Par headed into this earnings release with the stock grinding lower for months, down about 8% over the last quarter, even as its P/E sat below the wider Asian pharmaceuticals pack. The headline in this half-year period is profitability. Net income of about S$107.9m on revenue of S$115.9m translates into very high margins, which matters far more than the soft share price tape.
For short term traders the drift in Haw Par may look uninspiring. For long term holders the focus is now on whether those rich margins and the current valuation can hold over the coming years.
Love Haw Par's rich margins but uneasy about the recent share price drift? Check out the 299 resilient stocks with low risk scores as a benchmark for stocks that pair resilience with stronger market support.
Prefer clean visual charts instead of scrolling through dense earnings tables for Haw Par? View a full picture of its margin profile and profitability history in an easy-to-scan format through the company report for Haw Par..
For investors leaning positive on Haw Par, the latest half keeps the focus firmly on profitability. Net income of S$107.9m on S$115.9m revenue leaves very wide margins intact. The trailing 12 month net income of S$229.2m against S$219.6m revenue also points to strong earnings power over a longer window, even after a softer H1. That supports the idea of a brand backed, asset supported group where earnings quality, rather than rapid top line expansion, sits at the centre of the bullish argument.
The bearish side will highlight that H1 2026 revenue and net income are both lower than H1 2025, while the share price has fallen about 8% over 90 days. That lines up with concerns that Haw Par may not see a straight line in earnings across cycles and that the market remains unconvinced. Even with very strong margins, the step down in profit and earnings per share keeps alive worries about how resilient each business segment is when conditions are less supportive.
After a period of softer revenue and a dividend that is not well covered by free cash flows, it is fair to ask whether Haw Par has other structural vulnerabilities that are not obvious from headline margins alone. Review the independent risk analysis for Haw Par which shows 1 important warning signIf Haw Par's strong margins but softer recent share price have caught your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a more appealing entry point. When you decide to take a position, use the Portfolio Command Center to keep your holdings organised and surface only the most important developments. For a broader view on Haw Par and similar stocks, tap into the Community to compare your thinking with thousands of other investors. This way you can spot hidden catalysts or emerging risks early and stay a step ahead of the market.
Fresh stock ideas can start moving fast once momentum builds. Use these focused shortlists before the crowd catches on and information goes stale. Get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com